SUMMARY The neuroleptic malignant syndrome is a rare but dangerous complication of treatment with neuroleptics. The aetiology and pathophysiology of the syndrome are reviewed, and a fatal case is presented where both brain and muscle pathology are described. Striking myopathic changes in this case, accompanied by only minimal and non-specific brain abnormalities, support a peripheral rather than central mechanism for the hyperthermia.
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The term neuroleptic malignant syndrome was introduced into English medical literature by Delay and Deniker' in 1968, and since an article by Caroff 2 in 1980 interest in the syndrome has flourished.>' It is a rare8'0 but potentially fatal hypersensitivity response in certain patients exposed to neuroleptic medication. The core features are a diffuse muscular rigidity (often with extrapyramidal or catatonic signs), hyperthemia, autonomic instability, and altered consciousness; typically these develop days or weeks after starting neuroleptic treatment and progress over 24-72 hours. Associated findings include a leucocytosis, elevated serum potassium, and elevated serum creatine phosphokinase (CPK), the latter reflecting skeletal muscle necrosis. Mortality is about 20%2 and is particularly associated with long acting (depot) neuroleptics, a diagnosis of schizophrenia, and organic brain disease. 6 The syndrome has been reported to occur in a wide range ofpsychiatric disorders apart from schizophrenia,3 8 Case report A 70 year old widow suffering chronic depression had been an inpatient on a longstay psychiatric ward for 2 years when she became suddenly distressed and unwell, with dyspnoea, tachycardia of 150, diffuse muscular rigidity, and a pyrexia of 39-4°C. Within 1 hour she became cyanosed, hypotensive (BP 80/30 mmHg), and deeply comatose, with generalised rigidity and marked hyperreflexia. Her treatment at this time included a MAOI (isocarboxazid 10 mg od) and a neuroleptic (chlorpromazine 25 mg tds).
After initial resuscitative measures, the patient was transferred to a general hospital, where she had a grand mal fit. Investigations revealed a mild neutrophil leucocytosis, elevated serum potassium (6 mmol/l) and CPK (3,300 IU/1) and a sinus tachycardia on ECG. Chest radiograph, blood glucose, lumbar puncture, serial blood cultures and CT ofthe head were normal.
Combining the clinical picture and the results of the initial investigations, a diagnosis of neuroleptic malignant syndrome was made. Treatment comprised discontinuation of all psychotropic drugs, cooling, intravenous fluids and anticonvulsants. Within 24 hours the patient's clinical state improved considerably; her muscle rigidity and pyrexia resolved, and she regained full consciousness. However, as a result of widespread rhabdomyolysis she developed acute renal failure from which she died some days later.
It is of interest that throughout the previous two years of inpatient care, the patient had developed an unexplained toxic confusional state on six occasions. During this period she had received neuroleptics intermittently. These episodes were characterised by acute confusion with restlessness and 
